Amgen Inc. [NASDAQ: AMGN] loss -1.32% or -3.31 points to close at $247.75 with a heavy trading volume of 5201123 shares. The company report on January 29, 2021 that Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results.
Amgen (NASDAQ:AMGN) announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, Feb. 2, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 5 p.m. EST. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen’s senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.
It opened the trading session at $252.48, the shares rose to $276.69 and dropped to $243.45, the range by which the price of stock traded the whole day. The daily chart for AMGN points out that the company has recorded -0.44% loss over the past six months. However, it is still -39.93% lower than its most recent low trading price.
If we look at the average trading volume of 2.50M shares, AMGN reached to a volume of 5201123 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Amgen Inc. [AMGN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMGN shares is $255.64 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMGN stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Daiwa Securities have made an estimate for Amgen Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 29, 2020. While these analysts kept the previous recommendation, UBS raised their target price to Neutral. The new note on the price target was released on October 28, 2020, representing the official price target for Amgen Inc. stock. Previously, the target price had yet another raise to $255, while Raymond James analysts kept a Outperform rating on AMGN stock.
The Average True Range (ATR) for Amgen Inc. is set at 7.22, with the Price to Sales ratio for AMGN stock in the period of the last 12 months amounting to 5.74. The Price to Book ratio for the last quarter was 13.23, with the Price to Cash per share for the same quarter was set at 21.35. Price to Free Cash Flow for AMGN in the course of the last twelve months was 21.89 with Quick ratio for the last quarter at 1.90.
Trading performance analysis for AMGN stock
Amgen Inc. [AMGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.70. With this latest performance, AMGN shares gained by 10.78% in over the last four-week period, additionally sinking by -0.44% over the last 6 months – not to mention a rise of 9.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMGN stock in for the last two-week period is set at 58.87, with the RSI for the last a single of trading hit 54.87, and the three-weeks RSI is set at 58.99 for Amgen Inc. [AMGN]. The present Moving Average for the last 50 days of trading for this stock 232.66, while it was recorded at 253.60 for the last single week of trading, and 237.25 for the last 200 days.
Amgen Inc. [AMGN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Amgen Inc. [AMGN] shares currently have an operating margin of +41.15 and a Gross Margin at +81.27. Amgen Inc.’s Net Margin is presently recorded at +33.71.
Return on Total Capital for AMGN is now 22.13, given the latest momentum, and Return on Invested Capital for the company is 19.85. Return on Equity for this stock inclined to 70.73, with Return on Assets sitting at 12.44. When it comes to the capital structure of this company, Amgen Inc. [AMGN] has a Total Debt to Total Equity ratio set at 314.60. Additionally, AMGN Total Debt to Total Capital is recorded at 75.88, with Total Debt to Total Assets ending up at 50.97. Long-Term Debt to Equity for the company is recorded at 282.62, with the Long-Term Debt to Total Capital now at 68.17.
Reflecting on the efficiency of the workforce at the company, Amgen Inc. [AMGN] managed to generate an average of $335,128 per employee. Receivables Turnover for the company is 5.65 with a Total Asset Turnover recorded at a value of 0.37.Amgen Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.30.
Amgen Inc. [AMGN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Amgen Inc. posted 3.64/share EPS, while the average EPS was predicted by analysts to be reported at 3.46/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amgen Inc. go to 6.60%.
An analysis of insider ownership at Amgen Inc. [AMGN]
There are presently around $108,818 million, or 78.10% of AMGN stock, in the hands of institutional investors. The top three institutional holders of AMGN stocks are: BLACKROCK INC. with ownership of 47,985,428, which is approximately -1.527% of the company’s market cap and around 0.19% of the total institutional ownership; VANGUARD GROUP INC, holding 47,937,060 shares of the stock with an approximate value of $11.88 billion in AMGN stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $8.3 billion in AMGN stock with ownership of nearly 0.418% of the company’s market capitalization.
Positions in Amgen Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 1,009 institutional holders increased their position in Amgen Inc. [NASDAQ:AMGN] by around 17,602,249 shares. Additionally, 885 investors decreased positions by around 24,547,454 shares, while 314 investors held positions by with 397,074,147 shares. The mentioned changes placed institutional holdings at 439,223,850 shares, according to the latest SEC report filing. AMGN stock had 130 new institutional investments in for a total of 973,821 shares, while 103 institutional investors sold positions of 1,379,363 shares during the same period.